ArticleBMC cancer2025
Evaluating the anticancer properties of VAF: a novel folate-α-tocopherol conjugate against lung cancer cells.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring fetal skeletal alterations induced by gold nanoparticles in mice confirmed by laser speckle imaging and LIBS approach.Biology direct · 2026Article
- A Review of the Progress in the Microbial Biosynthesis of Prenylated Aromatic Compounds.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this study, a new chemical folate conjugated to α-tocopherol (VAF) is introduced. The main goal is to investigate the potential of VAF as a strong anticancer agent. This improves the drug-targeting delivery system and lessens the negative effects associated with traditional chemotherapy. PROCEDURE: To synthesize VAF, α-tocopherol, and folic acid were linked by a peptide bond, creating an amphiphilic structure that allowed for self-assembly in aqueous conditions. With an emphasis on evaluating VAF's capacity to target folate receptors, In vitro experiments were carried out utilizing A549 lung cancer cells to assess the anticancer effects of VAF.
resultsVAF was synthesized under mild circumstances, and its characterization was carried out using many analytical techniques, such as FTIR spectroscopy and NMR. In vitro investigations showed that VAF's improved active targeting via folate receptors results in excellent anticancer effects. Additionally, the cell viability of Wi-38 and A549 was assessed by using confocal laser scanning microscopy (CLSM).
conclusionAccording to the research, VAF reduces the possibility of adverse effects while increasing the efficacy of anticancer treatments. The compound exhibits promising properties that make it a great option for additional research and development in cancer treatments. Research provides important new information about drug-targeting delivery systems and improves a potentially useful method for anticancer drug therapeutic indices.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.